How digitalization M&A performed in the pharmaceutical industry in Q2 2023
In value terms, digitalization-related deal activity decreased by 100% in Q2 2023 compared with the previous quarter’s total of $145m and fell by 100% as compared to Q2 2022. Related deal volume increased by 11% in Q2 2023 versus the previous quarter and was 150% higher than in Q2 2022.
The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Wilson Sonsini Goodrich & Rosati Professional; Dua & Associates; Fasken Martineau DuMoulin with 2, 1, 1 deals respectively.
For further understanding of GlobalData’s Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.
Source link
#digitalization #performed #pharmaceutical #industry
